Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $20
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $18 to $20.
Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $18 to $20.